

# FAST FACTS


## The Medipattern Corporation

(September 30, 2008)

(TSX-V: MKI)

<b>Symbol:</b>	<b>TSX-V:MKI</b>
<b>Recent Price:</b>	<b>\$0.60</b>
<b>52-week High/Low:</b>	<b>\$ 0.50 - \$ 1.65</b>
<b>Shares Outstanding:</b>	<b>43.655 million</b>
<b>Warrants O/S (August 09/\$1.10):</b>	<b>312,234</b>
<b>Options O/S:</b>	<b>3,121,000</b>
<b>Market Capitalization:</b>	<b>\$26.2 million</b>

### 12-Month Share Price & Volume



### Analyst Coverage

Jon Hykawy	Research Capital
Douglas Loe	Versant Partners
Steven Gold	Clarus Securities

### Knowledge-Based Imaging

The Medipattern Corporation is the award-winning leader in computer-aided detection (CAD) software for breast ultrasound imaging. The Company's lead product is B-CAD®, a CAD software application designed to analyze breast ultrasound images. B-CAD automatically analyzes, segments, and classifies various physical and morphological characteristics to assist radiologists in characterizing breast lesions imaged with ultrasound. Medipattern recently released version 2.0 of this product, now available in Canada. B-CAD is based on Medipattern's CADENZA™ platform, and the second application in the CADENZA suite is B-CAD MRI™, an award-winning CAD software that for the first time enables those looking at MRI images to combine information contained in the morphological data with the more traditional kinetic data in their image analysis.

### Platform Technology

- Proprietary
- 1<sup>st</sup> FDA cleared CAD for Breast Ultrasound Imaging
- Proven application across multiple modalities: Ultrasound and MRI

### Product Highlights

- Marketing the first commercial applications for the analysis of breast ultrasound imaging.
- Productizing the first MRI CAD to enable morphological analysis of breast MRI.
- Achieved 510(k) clearance from the US Food and Drug Administration (FDA) followed by QMS ISO 13485 2003, CMDCAS, and CE medical certification, enabling sales across North America and Europe.
- Most recent clearance, SFDA received from the People's Republic of China.
- Awarded Frost & Sullivan's 2008 Best Practices Award.
- Awarded Frost & Sullivan's 2006 Medical Imaging Technology Innovation award for B-CAD MRI, and 2006 Product Innovation Award for B-CAD.

### Recent Developments

- Completed bought deal agreement for \$5.2 million plus over-allotment for a total of \$5.7 million.
- Signed 5-year collaborative sales & development agreement with \$17 billion imaging giant, GE Healthcare.
- Signed strategic partnership agreement with Confirma, the leading MRI provider, to deliver B-CAD MRI to Confirma's CADstream customers.
- Inked agreement with whole breast ultrasound developer, SonoCine, to create customized version of B-CAD and provide PACS viewing software for their product line.
- Integrated lead B-CAD product with breast imaging workstations of Sectra, a Swedish IT and medical technology company.
- Expanded global reseller network through agreements with Electronica y Medicina, S.A., Mexico; D.F., Mexico; Dong Jin Medical Co., Ltd., based in Seoul, Korea; DISS, San Juan; EMSOR, Madrid, Spain; Beijing East-wide Medical, Ltd., Beijing; and others.
- Installed more than 60 systems to date globally.